Association of blood lipids with Alzheimer's disease: A comprehensive lipidomics analysis

Alzheimer's and Dementia

Volumn 13, Issue 2, 2017, Pages 140-151

  Proitsi, Petroula ^a   Kim, Min ^b   Whiley, Luke ^b   Simmons, Andrew ^a,c   Sattlecker, Martina ^a,c   Velayudhan, Latha ^a   Lupton, Michelle K ^d   Soininen, Hillka ^e   Kloszewska, Iwona ^f   Mecocci, Patrizia ^g   Tsolaki, Magda ^h   Vellas, Bruno ⁱ   Lovestone, Simon ^j   Powell, John F ^a   Dobson, Richard J B ^a,c,k   Legido Quigley, Cristina ^b  

^a KING'S COLLEGE LONDON   (United Kingdom)

^b KING'S COLLEGE LONDON   (United Kingdom)

^c SOUTH LONDON AND MAUDSLEY NHS FOUNDATION TRUST   (United Kingdom)

^d QIMR BERGHOFER MEDICAL RESEARCH INSTITUTE   (Australia)

^e UNIVERSITY OF EASTERN FINLAND   (Finland)

^f MEDICAL UNIVERSITY OF LODZ   (Poland)

^g UNIVERSITY OF PERUGIA   (Italy)

^h ARISTOTLE UNIVERSITY OF THESSALONIKI   (Greece)

ⁱ Faculté de Médecine Centre Hospitalo universitaire   (France)

^j WARNEFORD HOSPITAL   (United Kingdom)

^k UNIVERSITY COLLEGE LONDON   (United Kingdom)

more..

Author keywords

Alzheimer's disease; Biomarkers; Brain atrophy; Classification; Dementia; Lipidomics; Machine learning; Metabolomics; Multivariate; Random forest; Rate of cognitive decline; sMRI

Indexed keywords

CHOLESTEROL ESTER; LIPID; PHOSPHATIDYLCHOLINE; TRIACYLGLYCEROL; BIOLOGICAL MARKER;

AGED; ALZHEIMER DISEASE; ARTICLE; BLOOD SAMPLING; BRAIN ATROPHY; CONTROLLED STUDY; DISEASE COURSE; ENTORHINAL CORTEX; FEMALE; GENOTYPE; HUMAN; IONIZATION; LEFT HIPPOCAMPUS; LIPID BLOOD LEVEL; LIPIDOMICS; MAJOR CLINICAL STUDY; MALE; PHENOTYPE; PRIORITY JOURNAL; RANDOM FOREST; RIGHT HIPPOCAMPUS; ATROPHY; BLOOD; COHORT ANALYSIS; DIAGNOSTIC IMAGING; DISEASE EXACERBATION; HIPPOCAMPUS; MULTIVARIATE ANALYSIS; NUCLEAR MAGNETIC RESONANCE IMAGING; REGRESSION ANALYSIS;

AGED; ALZHEIMER DISEASE; ATROPHY; BIOMARKERS; COHORT STUDIES; DISEASE PROGRESSION; ENTORHINAL CORTEX; FEMALE; HIPPOCAMPUS; HUMANS; LIPIDS; MAGNETIC RESONANCE IMAGING; MALE; MULTIVARIATE ANALYSIS; REGRESSION ANALYSIS;

EID: 85006056426     PISSN: 15525260     EISSN: 15525279     Source Type: Journal    
DOI: 10.1016/j.jalz.2016.08.003     Document Type: Article

References (44)

1. [1] Mapstone, M., Cheema, A.K., Fiandaca, M.S., Zhong, X., Mhyre, T.R., MacArthur, L.H., et al. Plasma phospholipids identify antecedent memory impairment in older adults. Nat Med 20 (2014), 415–418.
2. [2] Oresic, M., Hyotylainen, T., Herukka, S.K., Sysi-Aho, M., Mattila, I., Seppanan-Laakso, T., et al. Metabolome in progression to Alzheimer's disease. Transl Psychiatry, 1, 2011, e57.
3. [3] Trushina, E., Dutta, T., Persson, X.M., Mielke, M.M., Petersen, R.C., Identification of altered metabolic pathways in plasma and CSF in mild cognitive impairment and Alzheimer's disease using metabolomics. PLoS One, 8, 2013, e63644.
4. [4] Whiley, L., Sen, A., Heaton, J., Proitsi, P., Garcia-Gomez, D., Leung, R., et al. Evidence of altered phosphatidylcholine metabolism in Alzheimer's disease. Neurobiol Aging 35 (2014), 271–278.
5. [5] Zipser, B.D., Johanson, C.E., Gonzalez, L., Berzin, T.M., Tavares, R., Hulette, C.M., et al. Microvascular injury and blood-brain barrier leakage in Alzheimer's disease. Neurobiol Aging 28 (2007), 977–986.
6. [6] Lindon, J.C., Holmes, E., Nicholson, J.K., Metabonomics in pharmaceutical R&D. FEBS J 274 (2007), 1140–1151.
7. [7] Suhre, K., Shin, S.Y., Petersen, A.K., Mohney, R.P., Meredith, D., Wagele, B., et al. Human metabolic individuality in biomedical and pharmaceutical research. Nature 477 (2011), 54–60.
8. [8] Simpson, B.N., Kim, M., Chuang, Y.F., Beason-Held, L., Kitner-Triolo, M., Kraut, M., et al. Blood metabolite markers of cognitive performance and brain function in aging. J Cereb Blood Flow Metab 36 (2016), 1212–1223.
9. [9] Proitsi, P., Kim, M., Whiley, L., Pritchard, M., Leung, R., Soininen, H., et al. Plasma lipidomics analysis finds long chain cholesteryl esters to be associated with Alzheimer's disease. Transl Psychiatry, 5, 2015, e494.
10. [10] Lovestone, S., Francis, P., Kloszewska, I., Mecocci, P., Simmons, A., Soininen, H., et al. AddNeuroMed–the European collaboration for the discovery of novel biomarkers for Alzheimer's disease. Ann N Y Acad Sci 1180 (2009), 36–46.
11. [11] Whiley, L., Godzien, J., Ruperez, F.J., Legido-Quigley, C., Barbas, C., In-vial dual extraction for direct LC-MS analysis of plasma for comprehensive and highly reproducible metabolic fingerprinting. Anal Chem 84 (2012), 5992–5999.
12. [12] Whiley, L., Legido-Quigley, C., Current strategies in the discovery of small-molecule biomarkers for Alzheimer's disease. Bioanalysis 3 (2011), 1121–1142.
13. [13] Smith, C.A., Want, E.J., O'Maille, G., Abagyan, R., Siuzdak, G., XCMS: processing mass spectrometry data for metabolite profiling using nonlinear peak alignment, matching, and identification. Anal Chem 78 (2006), 779–787.
14. [14] Westman, E., Aguilar, C., Muehlboeck, J.S., Simmons, A., Regional magnetic resonance imaging measures for multivariate analysis in Alzheimer's disease and mild cognitive impairment. Brain Topogr 26 (2013), 9–23.
15. [15] Simmons, A., Westman, E., Muehlboeck, S., Mecocci, P., Vellas, B., Tsolaki, M., et al. MRI measures of Alzheimer's disease and the AddNeuroMed study. Ann N Y Acad Sci 1180 (2009), 47–55.
16. [16] Simmons, A., Westman, E., Muehlboeck, S., Mecocci, P., Vellas, B., Tsolaki, M., et al. The AddNeuroMed framework for multi-centre MRI assessment of Alzheimer's disease: experience from the first 24 months. Int J Geriatr Psychiatry 26 (2011), 75–82.
17. [17] Sattlecker, M., Kiddle, S.J., Newhouse, S., Proitsi, P., Nelson, S., Williams, S., et al. Alzheimer's disease biomarker discovery using SOMAscan multiplexed protein technology. Alzheimers Dement 10 (2014), 724–734.
18. [18] Wilson, R.S., Arnold, S.E., Schneider, J.A., Kelly, J.F., Tang, Y., Bennett, D.A., Chronic psychological distress and risk of Alzheimer's disease in old age. Neuroepidemiology 27 (2006), 143–153.
19. [19] Walter, A., Korth, U., Hilgert, M., Hartmann, J., Weichel, O., Hilgert, M., et al. Glycerophosphocholine is elevated in cerebrospinal fluid of Alzheimer patients. Neurobiol Aging 25 (2004), 1299–1303.
20. [20] Koal, T., Klavins, K., Seppi, D., Kemmler, G., Humpel, C., Sphingomyelin SM(d18:1/18:0) is significantly enhanced in cerebrospinal fluid samples dichotomized by pathological amyloid-beta42, tau, and phospho-tau-181 levels. J Alzheimers Dis 44 (2015), 1193–1201.
21. [21] Gonzalez-Dominguez, R., Garcia-Barrera, T., Gomez-Ariza, J.L., Combination of metabolomic and phospholipid-profiling approaches for the study of Alzheimer's disease. J Proteomics 104 (2014), 37–47.
22. [22] St-Onge, M.P., Mayrsohn, B., O'Keeffe, M., Kissileff, H.R., Choudhury, A.R., Laferrere, B., Impact of medium and long chain triglycerides consumption on appetite and food intake in overweight men. Eur J Clin Nutr 68 (2014), 1134–1140.
23. [23] Stegemann, C., Pechlaner, R., Willeit, P., Langley, S.R., Mangino, M., Mayr, U., et al. Lipidomics profiling and risk of cardiovascular disease in the prospective population-based Bruneck study. Circulation 129 (2014), 1821–1831.
24. [24] Rhee, E.P., Cheng, S., Larson, M.G., Walford, G.A., Lewis, G.D., McCabe, E., et al. Lipid profiling identifies a triacylglycerol signature of insulin resistance and improves diabetes prediction in humans. J Clin Invest 121 (2011), 1402–1411.
25. [25] Montoliu, I., Scherer, M., Beguelin, F., DaSilva, L., Mari, D., Salvioli, S., et al. Serum profiling of healthy aging identifies phospho- and sphingolipid species as markers of human longevity. Aging (Albany NY) 6 (2014), 9–25.
26. [26] Henderson, S.T., Vogel, J.L., Barr, L.J., Garvin, F., Jones, J.J., Costantini, L.C., Study of the ketogenic agent AC-1202 in mild to moderate Alzheimer's disease: a randomized, double-blind, placebo-controlled, multicenter trial. Nutr Metab (Lond), 6, 2009, 31.
27. [27] Proitsi, P., Lupton, M.K., Velayudhan, L., Newhouse, S., Fogh, I., Tsolaki, M., et al. Genetic predisposition to increased blood cholesterol and triglyceride lipid levels and risk of Alzheimer disease: a mendelian randomization analysis. PLoS Med, 11, 2014, e1001713.
28. [28] Desikan, R.S., Schork, A.J., Wang, Y., Thompson, W.K., Dehghan, A., Ridker, P.M., et al. Polygenic Overlap Between C-Reactive Protein, Plasma Lipids, and Alzheimer Disease. Circulation 131 (2015), 2061–2069.
29. [29] Crameri, A., Biondi, E., Kuehnle, K., Lutjohann, D., Thelen, K.M., Perga, S., et al. The role of seladin-1/DHCR24 in cholesterol biosynthesis, APP processing and Abeta generation in vivo. EMBO J 25 (2006), 432–443.
30. [30] Greeve, I., Kretzschmar, D., Tschape, J.A., Beyn, A., Brellinger, C., Schweizer, M., et al. Age-dependent neurodegeneration and Alzheimer-amyloid plaque formation in transgenic Drosophila. J Neurosci 24 (2004), 3899–3906.
31. [31] Sato, Y., Suzuki, I., Nakamura, T., Bernier, F., Aoshima, K., Oda, Y., Identification of a new plasma biomarker of Alzheimer's disease using metabolomics technology. J Lipid Res 53 (2012), 567–576.
32. [32] Wisniewski, T., Newman, K., Javitt, N.B., Alzheimer's disease: brain desmosterol levels. J Alzheimers Dis 33 (2013), 881–888.
33. [33] Reitz, C., Mayeux, R., Alzheimer disease: epidemiology, diagnostic criteria, risk factors and biomarkers. Biochem Pharmacol 88 (2014), 640–651.
34. [34] Reitz, C., Dyslipidemia and the risk of Alzheimer's disease. Curr Atheroscler Rep, 15, 2013, 307.
35. [35] Reitz, C., Dyslipidemia and dementia: current epidemiology, genetic evidence, and mechanisms behind the associations. J Alzheimers Dis 30 (2012), S127–S145.
36. [36] Rowland, A.A., Voeltz, G.K., Endoplasmic reticulum-mitochondria contacts: function of the junction. Nat Rev Mol Cell Biol 13 (2012), 607–625.
37. [37] Helle, S.C., Kanfer, G., Kolar, K., Lang, A., Michel, A.H., Kornmann, B., Organization and function of membrane contact sites. Biochim Biophys Acta 2013 (1833), 2526–2541.
38. [38] van Vliet, A., Verfaillie, T., Agostinis, P., New functions of mitochondria associated membranes in cellular signalling. Biochim Biophys Acta 1843 (2014), 2253–2262.
39. [39] Area-Gomez, E., Del Carmen Lara Castillo, M., Tambini, M.D., Guardia-Laguarta, C., de Groof, A.J., Madra, M., et al. Upregulated function of mitochondria-associated ER membranes in Alzheimer disease. EMBO J 31 (2012), 4106–4123.
40. [40] Zampese, E., Fasolato, C., Kipanyula, M.J., Bortolozzi, M., Pozzan, T., Pizzo, P., Presenilin 2 modulates endoplasmic reticulum (ER)-mitochondria interactions and Ca2+ cross-talk. Proc Natl Acad Sci U S A 108 (2011), 2777–2782.
41. [41] Sepulveda-Falla, D., Barrera-Ocampo, A., Hagel, C., Korwitz, A., Vinueza-Veloz, M.F., Zhou, K., et al. Familial Alzheimer's disease-associated presenilin-1 alters cerebellar activity and calcium homeostasis. J Clin Invest 124 (2014), 1552–1567.
42. [42] Hedskog, L., Pinho, C.M., Filadi, R., Ronnback, A., Hertwig, L., Wiehager, B., et al. Modulation of the endoplasmic reticulum-mitochondria interface in Alzheimer's disease and related models. Proc Natl Acad Sci U S A 110 (2013), 7916–7921.
43. [43] Tambini, M.D., Pera, M., Kanter, E., Yang, H., Guardia-Laguarta, C., Holtzman, D., et al. ApoE4 upregulates the activity of mitochondria-associated ER membranes. EMBO Rep 17 (2016), 27–36.
44. [44] Sen, A., Wang, Y., Chiu, K., Whiley, L., Cowan, D., Chang, R.C., et al. Metabolic phenotype of the healthy rodent model using in-vial extraction of dried serum, urine, and cerebrospinal fluid spots. Anal Chem 85 (2013), 7257–7263.